Two distant plants independently invented the same medicine

Sometimes research tells the story of Mother Nature playing the role of two inventors living continents apart and separated by millions of years, who somehow stumble upon the same clever solution to a tricky problem. Sure, nature pulls off similar feats all the time, but whenever a study reveals one of these examples, well, it's fascinating.

Researchers from the Max Planck Institute for Chemical Ecology in Germany, together with scientists from Brazil and Japan, have unraveled how two evolutionarily distant plants, Carapichea ipecacuanha, the source of the old-fashioned ipecac syrup, and Alangium salviifolium, a tree long used in Indian Ayurvedic medicine, manage to make the very same powerful compounds known as ipecac alkaloids. These molecules can induce vomiting, but they also have potential as treatments against cancer and malaria.

The team's findings, published in Nature Chemical Biology, explains a long-standing botanical mystery, showcases the incredible creativity of evolution, and may possibly pave the way for producing valuable plant medicines more efficiently in the lab.

Carapichea ipecacuanha, a small rainforest plant from South America, was once famous for its syrup: a potent remedy that doctors prescribed for centuries to make patients vomit after poisoning. Across the world in India, Alangium salviifolium, a tree locally known as Ankol(a), was used in traditional medicine for similar purposes.

What's remarkable is that these two species are not close relatives at all. In fact, they diverged on the tree of life roughly 150 million years ago. And yet, both plants independently figured out how to build the same unusual class of chemicals: ipecac alkaloids, including emetine and cephaeline. These compounds are derived from protoemetine, a molecular “ancestor” that both plants manage to produce, despite starting from different ingredients.

At the heart of the story is a chemical reaction with a very intimidating name: the Pictet–Spengler reaction. But don't let it scare you. Think of it as one of the ways nature has for snapping together two Lego blocks, dopamine (a simple brain chemical you've probably heard of) and a plant metabolite called secologanin or secologanic acid.

In most plants, special enzymes are needed to choreograph such chemical couplings. But in these two species, the reaction seems to happen on its own inside the cells of the plant, without a dedicated enzyme guiding it. The researchers showed that under the slightly acidic conditions inside plant vacuoles (tiny cellular storage bubbles), dopamine and secologanin practically glue themselves together.

That spontaneous start creates two slightly different versions (mirror-image isomers) of a molecule. From there, the enzymes of each plant take over, nudging the chemistry along to make protoemetine. Despite their evolutionary distance, both plants use strikingly similar sequences of steps, though with distinct enzymes that arose independently.

How could two plants separated by 150 million years end up with the same recipe? The researchers call this a case of parallel and convergent evolution. In parallel evolution, two species tweak different versions of the same ancestral enzyme to achieve a similar result. In convergent evolution, completely unrelated enzymes evolve to perform the same task, like two different lock designs that both fit the same key.

The ipecac alkaloid pathway shows both. Some enzymes in Carapichea and Alangium come from the same broad family but evolved separately. Others are from entirely different protein families that converged on the same job.

In other words, evolution ran the same experiment twice, and both times, it worked.

Understanding these pathways is extremely important. In fact, ipecac alkaloids aren’t only vomit-inducers. Compounds like emetine have shown promise as anti-cancer agents, while others in the family display anti-malarial activity. The problem is, harvesting them from plants is slow, and cultivating the plants is challenging.

By decoding the step-by-step genetic and chemical recipe, scientists can now imagine engineering microbes or crop plants to produce these alkaloids in a controlled, sustainable way. That could revive interest in these once-classic, now underused medicines, perhaps even leading to new drugs inspired by them. Basically, the study lays a foundation for metabolic engineering of these important medicinal compounds. Translation: we might soon be able to brew ipecac alkaloids in a lab, like beer, instead of digging up rare plants in tropical forests.

This research also tells a larger story. Plants are extraordinary chemists. Over hundreds of millions of years, they’ve filled the world with an astonishing diversity of natural compounds, caffeine in coffee, nicotine in tobacco, morphine in poppies. Sometimes, distant plants even reinvent the same molecule independently, as if evolution keeps finding the same winning lottery numbers.

The discovery in Carapichea and Alangium adds another example to a long list that demonstrates that life is both inventive and persistent: when a chemical pathway proves useful, whether for defense, survival, or medicinal value, evolution may stumble upon it more than once.

And in this case, that persistence may benefit us too, offering new routes to old medicines with fresh relevance in modern healthcare. More broadly, the story of ipecac alkaloids reminds us that natural medicines have deep evolutionary roots, sometimes stretching across continents and epochs. With modern science, we can now read and repurpose those evolutionary blueprints.

Who knows? The next anti-cancer or anti-malarial drug may come not from a rainforest root or a traditional syrup bottle, but from a bioreactor humming quietly in a laboratory, thanks to lessons learned from two plants that solved the same puzzle in parallel, 150 million years apart.

If you want to learn more, read the original article titled "Ipecac alkaloid biosynthesis in two evolutionarily distant plants" on Nature Chemical Biology at http://dx.doi.org/10.1038/s41589-025-01926-z.